GILD

Gilead Sciences, Inc. Press Releases

$69.05
*  
0.88
 negative 
1.29%
Get GILD Alerts
*Delayed - data as of Apr. 16, 2014 12:47 ET 
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    GILD Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Gilead Sciences to Release First Quarter 2014 Financial Results on Tuesday, April 22, 2014
4/15/2014 5:00:00 PM - Business Wire

Financial Release Dates -- Research on Gilead Sciences, Juniper Networks, FirstCommonwealth Financial, and Genuine Parts
4/14/2014 9:00:00 AM - PR Newswire

Gilead’s Sovaldi® Demonstrates Efficacy and Safety Among Chronic Hepatitis C Patients with Advanced Liver Disease
4/11/2014 1:02:00 AM - Business Wire

Today's Review on Active Stocks -- Research on Ashford Hospitality Trust, Dejour Energy, North American Palladium, and Gilead Sciences
4/10/2014 1:30:00 PM - PR Newswire

Gilead Announces Phase 2 Results for Two Investigational All-Oral Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C
4/10/2014 1:02:00 AM - Business Wire

Gilead Announces Results from Study of Sovaldi® for Retreatment of Chronic Hepatitis C in Patients Not Cured with Prior Antiviral Therapy
4/10/2014 1:02:00 AM - Business Wire

Gilead Announces U.S. FDA Priority Review Designation for Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Chronic Hepatitis C Genotype 1 Infection
4/7/2014 8:30:00 AM - Business Wire

Senior Notes Conversions, FDA Drug Approvals, Acquisitions, Stock Price Updates, and Clinical Trial Studies - Analyst Notes on Gilead, Pfizer, Nordion, Intuitive Surgical, and Novartis
4/3/2014 8:00:00 AM - PR Newswire

Gilead Announces Results From Phase 3 Study of Sofosbuvir Among Hepatitis C Patients in Japan
4/2/2014 4:30:00 PM - Business Wire

Pending Applications, Closed Public Offering, Joint Venture Formation, Executive Appointment, and Commercial Launch - Analyst Notes on Gilead, Enzymotec, Intrexon, Advaxis, and Repligen
4/1/2014 8:00:00 AM - PR Newswire

Janssen Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of HIV-1 Medicine Darunavir with Cobicistat as Part of Combination HIV Therapy
4/1/2014 7:45:00 AM - PR Newswire

Comprehensive Technical Coverage on Active Equities -- Research on Sirius XM, Gilead Sciences, Microsoft, and Yahoo!
3/31/2014 12:03:00 PM - PR Newswire

Gilead Announces Settlement Method for 1.00% Convertible Senior Notes Due 2014
3/28/2014 8:30:00 AM - Business Wire

European Medicines Agency Validates Gilead’s Marketing Application for Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Chronic Hepatitis C Infection
3/27/2014 4:10:00 PM - Business Wire

Idenix Pharmaceuticals Intends to Appeal Norway District Court Decision Regarding Patent Invalidity Case
3/24/2014 7:00:00 AM - GlobeNewswire

Investor-Edge.com Most Active Equities Watch List: Staples, Gilead Sciences, Office Depot, and Sprint
3/7/2014 8:00:00 AM - PR Newswire

Patient Support Programs, Financial Results, and Stock Price Movements - Analyst Notes on Gilead, Forest Laboratories, Thermo Fisher Scientific, HCA Holdings, and Nektar
3/6/2014 8:25:00 AM - PR Newswire

Gilead Prices $4 Billion of Senior Unsecured Notes
3/4/2014 6:15:00 PM - Business Wire

Gilead Sciences to Present at the 34th Cowen & Co. Healthcare Conference on Monday, March 3
2/28/2014 5:00:00 PM - Business Wire

Gilead Sciences to Present at the RBC Capital Markets 2014 Global Healthcare Conference on Wednesday, February 26
2/25/2014 5:00:00 PM - Business Wire

Gilead Sciences to Present at Two Upcoming Investor Conferences
2/10/2014 5:00:00 PM - Business Wire

Gilead Files for U.S. Approval of Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Hepatitis C
2/10/2014 4:05:00 PM - Business Wire

Gilead Sciences Announces Fourth Quarter and Full Year 2013 Financial Results
2/4/2014 4:05:00 PM - Business Wire

Mylan Named as Gilead's Exclusive Branded Medicines Business Partner for India
1/31/2014 12:30:00 AM - PR Newswire

Gilead Sciences to Release Fourth Quarter and Year End 2013 Financial Results on Tuesday, February 4, 2014
1/28/2014 5:00:00 PM - Business Wire